You are here:
boceprevir (Victrelis) Experienced Patients
Advice
following a full submission
boceprevir (Victrelis®) is accepted for use within NHS Scotland.
Indication under review: Treatment of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who have failed previous therapy.
In the pivotal phase III randomised study, addition of boceprevir to current standard therapy in patients with HCV, who had failed previous therapy, increased the proportion of patients who achieved a sustained virologic response.
Drug Details
| Drug Name: | boceprevir (Victrelis) Experienced Patients |
|---|---|
| SMC Drug ID: | 722/11 |
| Manufacturer: | Merck Sharp and Dohme Ltd |
| Indication: | Treatment of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who have failed previous therapy. |
| BNF Category: | |
| Sub Category: | 5.3 Antiviral Drugs |
| Submission Type: | Full submission |
| Status: | Accepted |
| Date Advice Published: | 10 October 2011 |